Additionally, supplementation with riboflavin (1.6 mg/d for 16 weeks) altered the DNAm status of hypertension-related genes (i.e., IGF2, ACE, GNA12, and AGTR1) in carriers of the MTHFR 677TT genotype, revealing an epigenomic mechanism linking hypertension risk with the allele-specific response of blood pressure to riboflavin intake [61]. This evidence concerns the gene ACE and hypertensive disorder.